What are you looking for?
A review of adverse events found relatively low complication rates associated with the Hydrus Microstent, iStent inject W, and iStent infinite glaucoma devices, according to a poster presented at the...
Results from a phase 2, randomized, single-masked clinical trial found that the overall safety of 8 mg intravitreal aflibercept injection (IAI) in patients with neovascular age-related macular degeneration (nAMD) is...
In patients who have undergone radiation, poor, long-term visual acuity outcomes are common. Data from a multi-center, prospective randomized clinical trial presented at ASRS 2022 found that intravitreal aflibercept injections...
Administering intravitreal pegcetacoplan monthly or every other month in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) is well tolerated at 12 months, according to safety data...
A machine learning (ML) algorithm was able to predict visual and anatomic outcomes in patients with macular edema secondary to central retinal vein occlusion (ME-CRVO) after undergoing treatment with aflibercept,...
Patients with macular edema due to central retinal vein occlusion (MEfCRVO) who did not receive their first intravitreal aflibercept injection (IAI) until >3 months after diagnosis had worse visual improvement...
Compared to general anesthesia (GA) for vitreoretinal surgeries, local anesthesia (LA) is more cost-effective and leads to an earlier discharge, according to a poster presented at ASRS 2022. In this...
Over a 2-year period, no significant differences in visual outcomes were found between treatment with aflibercept monotherapy and treatment with initial bevacizumab with a switch to aflibercept in the case...
The 52-week results from 2 phase 3 studies show that brolucizumab (Beovu; Novartis) provides robust vision improvements and superior anatomical outcomes with dosing every 12-week (q12w) intervals in more than...